Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 29;21(11):3869.
doi: 10.3390/ijms21113869.

Animal Models Used in Hepatitis C Virus Research

Affiliations
Review

Animal Models Used in Hepatitis C Virus Research

Keith A Berggren et al. Int J Mol Sci. .

Abstract

The narrow range of species permissive to infection by hepatitis C virus (HCV) presents a unique challenge to the development of useful animal models for studying HCV, as well as host immune responses and development of chronic infection and disease. Following earlier studies in chimpanzees, several unique approaches have been pursued to develop useful animal models for research while avoiding the important ethical concerns and costs inherent in research with chimpanzees. Genetically related hepatotropic viruses that infect animals are being used as surrogates for HCV in research studies; chimeras of these surrogate viruses harboring specific regions of the HCV genome are being developed to improve their utility for vaccine testing. Concurrently, genetically humanized mice are being developed and continually advanced using human factors known to be involved in virus entry and replication. Further, xenotransplantation of human hepatocytes into mice allows for the direct study of HCV infection in human liver tissue in a small animal model. The current advances in each of these approaches are discussed in the present review.

Keywords: animal model; hepatitis C; hepatitis C virus; host tropism; humanized mice.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the writing of the manuscript.

Similar articles

Cited by

References

    1. WHO . Global Hepatitis Report 2017. WHO; Geneva, Switzerland: 2018.
    1. Thrift A.P., El-Serag H.B., Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat. Rev. Gastroenterol. Hepatol. 2017;14:122–132. doi: 10.1038/nrgastro.2016.176. - DOI - PubMed
    1. Webster D.P., Klenerman P., Dusheiko G.M. Hepatitis C. Lancet. 2015;385:1124–1135. - PMC - PubMed
    1. Poordad F., Dieterich D. Treating hepatitis C: Current standard of care and emerging direct-acting antiviral agents. J. Viral Hepat. 2012;19:449–464. doi: 10.1111/j.1365-2893.2012.01617.x. - DOI - PubMed
    1. Pockros P.J. New direct-acting antivirals in the development for hepatitis C virus infection. Ther. Adv. Gastroenterol. 2010;3:191–202. doi: 10.1177/1756283X10363055. - DOI - PMC - PubMed